Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Reata Pharmaceuticals, Inc is a biotechnology business based in the US. Reata Pharmaceuticals shares (RETA) are listed on the NASDAQ and all prices are listed in US Dollars. Reata Pharmaceuticals employs 220 staff and has a trailing 12-month revenue of around USD$8.5 million.
Since the stock market crash in March caused by coronavirus, Reata Pharmaceuticals's share price has had significant negative movement.
Its last market close was USD$170.4, which is 19.30% down on its pre-crash value of USD$211.14 and 50.78% up on the lowest point reached during the March crash when the shares fell as low as USD$113.01.
If you had bought USD$1,000 worth of Reata Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$536.39 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$707.16.
|Latest market close||USD$170.4|
|52-week range||USD$88.17 - USD$257.965|
|50-day moving average||USD$135.3817|
|200-day moving average||USD$134.5608|
|Wall St. target price||USD$245.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.056|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-19)||N/A|
|1 month (2020-10-30)||46.00%|
|3 months (2020-08-26)||N/A|
|6 months (2020-05-26)||N/A|
|1 year (2019-11-26)||N/A|
|2 years (2018-11-26)||N/A|
|3 years (2017-11-26)||N/A|
|5 years (2015-11-26)||N/A|
|Revenue TTM||USD$8.5 million|
|Gross profit TTM||USD$-225,990,000|
|Return on assets TTM||-49.7%|
|Return on equity TTM||-623.06%|
|Market capitalisation||USD$5.1 billion|
TTM: trailing 12 months
There are currently 3.1 million Reata Pharmaceuticals shares held short by investors – that's known as Reata Pharmaceuticals's "short interest". This figure is 8.5% down from 3.4 million last month.
There are a few different ways that this level of interest in shorting Reata Pharmaceuticals shares can be evaluated.
Reata Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Reata Pharmaceuticals shares currently shorted divided by the average quantity of Reata Pharmaceuticals shares traded daily (recently around 265630.23850085). Reata Pharmaceuticals's SIR currently stands at 11.74. In other words for every 100,000 Reata Pharmaceuticals shares traded daily on the market, roughly 11740 shares are currently held short.
However Reata Pharmaceuticals's short interest can also be evaluated against the total number of Reata Pharmaceuticals shares, or, against the total number of tradable Reata Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Reata Pharmaceuticals's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Reata Pharmaceuticals shares in existence, roughly 90 shares are currently held short) or 0.1448% of the tradable shares (for every 100,000 tradable Reata Pharmaceuticals shares, roughly 145 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Reata Pharmaceuticals.
Find out more about how you can short Reata Pharmaceuticals stock.
We're not expecting Reata Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Reata Pharmaceuticals's shares have ranged in value from as little as $88.17 up to $257.965. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Reata Pharmaceuticals's is 1.5686. This would suggest that Reata Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.